Answers are grounded in this paper and cite their sources.
We exploited dendritic cells (DC) to vaccinate melanoma patients. We recently demonstrated a statistical significant correlation between favorable clinical outcome and the presence of vaccine-related tumor antigen-specific T cells in delayed type hypersensitivity (DTH) skin biopsies. However, favorable clinical outcome is only observed in a minority of the treated patients. Therefore, it is obvious that current DC-based protocols need to be improved. For this reason, we study in small proof of principle trials the fate, interactions and effectiveness of the injected DC.
No takes yet. Share an insight, caveat, or question.
Aarntzen et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: